Feasibility study to investigate the effect of Acanthopanax senticosus intake on the cancer related fatigue.

Not Applicable

• Conditions: Cancer related fatigue (malaise)

• Registration Number: JPRN-UMIN000035464
• Lead Sponsor: Health Sciences University of Hokkaido

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-07
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

Not provided

Exclusion Criteria

# The patients who have taken Acanthopanax Senticosus and are not off it for more than 3 months. # Allergy to Acanthopanax Senticosus and/or honey. # Uterus and Ovary cancer patient who are histologically confirmed with estrogen receptor positive. # The patient who received Doxifluridine (FURTULON) chemotherapy. # Uncontrolled hypertension (Blood pressure more than 180/90 mmHg) # Currently taking digoxin formulation. # Co-existence of severe complication. # Pregnant or expected to be pregnant, and breast feeding mother. # Co-existence of endometriosis and myoma uteri. # Unable to provide and written informed consent due to mental disorder. # Concomitant use of drugs which is contraindicated towards Acanthopanax Senticosus.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of the patient whose BFI and FACIT-F can be evaluated at day 28.

Secondary Outcome Measures

Name	Time	Method
# The changes in BFI score during registration and day 29. # The changes in FACIT-F subscale score during registration and day 29. # The changes in FACIT-F total score during registration and day 28. # Safety (The frequency of total adverse event). # General condition (assessed by ECOG-PS). # The changes in laboratory data.